18α-glycyrrhetinic acid extracted from Glycyrrhiza radix inhibits proliferation and promotes apoptosis of the hepatic stellate cell line

Journal of Digestive Diseases

Volumn 14, Issue 6, 2013, Pages 328-336

  Zong, Lei ^a,b   Qu, Ying ^a   Xu, Ming Yi ^a   Dong, Yu Wei ^a   Lu, Lun Gen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b WEIFANG PEOPLE'S HOSPITAL   (China)

Author keywords

18 glycyrrhetinic acid; Apoptosis; Hepatic stellate cells; NF kappa B; Peroxisome proliferator activated receptors; Proliferation

Indexed keywords

18ALPHA GLYCYRRHETINIC ACID; 2 CHLORO 5 NITROBENZANILIDE; CARBON TETRACHLORIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ASSAY; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; FLOW CYTOMETRY; GLYCYRRHIZA; GLYCYRRHIZA RADIX; HUMAN; HUMAN CELL; ITO CELL; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STELLATE CELL; WESTERN BLOTTING;

ANILIDES; ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCYRRHETINIC ACID; GLYCYRRHIZA; HEPATIC STELLATE CELLS; HUMANS; NF-KAPPA B; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS;

EID: 84876957204     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12041     Document Type: Article

References (35)

1. Bissell DM. Hepatic fibrosis as wound repair: a progress report. J Gastroenterol 1998; 33: 295-302.
2. Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009; 25: 223-229.
3. Urtasun R, Nieto N. Hepatic stellate cells and oxidative stress. Rev Esp Enferm Dig 2007; 99: 223-230 (in Spanish).
4. Comporti M, Arezzini B, Signorini C, Vecchio D, Gardi C. Oxidative stress, isoprostanes and hepatic fibrosis. Histol Histopathol 2009; 24: 893-900.
5. Wu X, Zhang L, Gurley E etal. Prevention of free fatty acid-induced hepatic lipotoxicity by 18β-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 2008; 47: 1905-1915.
6. Abbott BD. Review of the expression of peroxisome proliferator-activated receptors alpha (PPARα), beta (PPARβ), and gamma (PPARγ) in rodent and human development. Reprod Toxicol 2009; 27: 246-257.
7. Fujii D, Yoshida K, Tanabe K, Hihara J, Toge T. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest. Anticancer Res 2004; 24: 1409-1416.
8. Biscetti F, Gaetani E, Flex A etal. Selective activation of peroxisome proliferator-activated receptor (PPAR)α and PPARγ induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 2008; 57: 1394-1404.
9. Desouza CV, Gerety M, Hamel FG. Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells. Vascul Pharmacol 2009; 51: 162-168.
10. Lu X, Murphy TC, Nanes MS, Hart CM. PPARγ regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-κB. Am J Physiol Lung Cell Mol Physiol 2010; 299: L559-566.
11. Gao DF, Niu XL, Hao GH etal. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-γ in vascular fibrosis. Biochem Pharmacol 2007; 73: 185-197.
12. Yu J, Zhang S, Chu ES etal. Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro. Int J Biochem Cell Biol 2010; 42: 948-957.
13. Yoke YC, So HT, Abdul KK. Effects of glycyrrhizic acid on peroxisome proliferator-activated receptor gamma (PPARγ), lipoprotein lipase (LPL), serum lipid and HOMA-IR in rats. PPAR Res 2010; 2010: 530265.
14. Xu L, Hui AY, Albanis E etal. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005; 54: 142-151.
15. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 2000; 285: 194-204.
16. Lee KS, Park JH, Lee S, Lim HJ, Jang Y, Park HY. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochem Biophys Res Commun 2006; 346: 83-88.
17. Yu HN, Lee YR, Noh EM etal. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor γ (PPARγ) ligand. Cell Biol Int 2008; 32: 906-912.
18. Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009; 28: 2925-2939.
19. Rizzolio F, Tuccinardi T, Caligiuri I, Lucchetti C, Giordano A. CDK inhibitors: from the bench to clinical trials. Curr Drug Targets 2010; 11: 279-290.
20. Chen W, Gao N, Shen Y, Cen JN. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol 2010; 25: 823-831.
21. Sakai K, Oka K, Matsumoto K, Nakamura T. p27 Nuclear localization and growth arrest caused by perlecan knockdown in human endothelial cells. Biochem Biophys Res Commun 2010; 392: 403-408.
22. Yang X, Yang S, McKimmey C etal. Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation. Carcinogenesis 2010; 31: 695-702.
23. KIP1 via paracrine mechanisms. Eur J Cancer 2010; 46: 974-982.
24. Patel MP, Masood A, Patel PS, Chanan-Khan AA. Targeting the Bcl-2. Curr Opin Oncol 2009; 21: 516-523.
25. Wan F, Lenardo MJ. The nuclear signaling of NF-κB: current knowledge, new insights, and future perspectives. Cell Res 2010; 20: 24-33.
26. Kim JK, Kim KD, Lee E etal. Up-regulation of Bfl-1/A1 via NF-κB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett 2004; 212: 61-70.
27. Wei-guo Z, Hui Y, Shan L etal. PPAR-γ agonist inhibits Ang II-induced activation of dendritic cells via the MAPK and NF-κB pathways. Immunol Cell Biol 2010; 88: 305-312.
28. Wahli W. A gut feeling of the PXR, PPAR and NF-κB connection. J Intern Med 2008; 263: 613-619.
29. Feinstein DL, Spagnolo A, Akar C etal. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 2005; 70: 177-188.
30. Sung B, Park S, Yu BP, Chung HY. Amelioration of age-related inflammation and oxidative stress by PPARγ activator: suppression of NF-κB by 2, 4-thiazolidinedione. Exp Gerontol 2006; 41: 590-599.
31. Chen F, Wang M, O'Connor JP, He M, Tripathi T, Harrison LE. Phosphorylation of PPARγ via active ERK1/2 leads to its physical association with p65 and inhibition of NF-κB. J Cell Biochem 2003; 90: 732-744.
32. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003; 85: 267-273.
33. Ban JO, Kwak DH, Oh JH etal. Suppression of NF-κB and GSK-3β is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact 2010; 188: 75-85.
34. Jiang JX, Mikami K, Venugopal S, Li Y, Török NJ. Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-κB-dependent pathways. J Hepatol 2009; 51: 139-148.
35. Takase O, Minto AW, Puri TS etal. Inhibition of NF-κB-dependent Bcl-xL expression by clusterin promotes albumin-induced tubular cell apoptosis. Kidney Int 2008; 73: 567-577.